NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

218.7B

Vuru Grade

66.34/100

Current Price

$90.15
+0.91 (+1.02%)

Growth Price

$67.73
Overvalued by 24.87%

Stability Price

$24.64
Overvalued by 72.66%

Company Metrics

  • 22.66 P/E
  • 3.65 P/S
  • 3.08 P/B
  • 3.938 EPS
  • 13.46% Cash ROIC
  • 0.35 Cash Ratio
  • 2.719 / 3.05% Dividend
  • 1.34M Avg. Vol.
  • 2.43B Shares
  • 218.7B Market Cap.

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Novartis Announces Positive Phase-III Results For Secukinumab
Bidness ETC - Oct 23, 2014
Novartis AG (ADR) (NVS) announced today that its experimental drug AIN457 (Secukinumab) met its primary and secondary end points in two late-stage trials called MEASURE 1 and MEASURE-2.
FDA Advisory Committee Votes In Favor Of Novartis' IL-17 Inhibitor
Bidness ETC - Oct 21, 2014
Novartis AG (ADR) (NVS) announced yesterday that the Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA has unanimously recommended the use of Novartis' AIN457 in adults who are suffering from moderate-to-severe plaque psoriasis.
Stocks in Focus- Bristol-Myers Squibb Co (NYSE:BMY), Novartis AG (ADR ...
StreetWise Report - 22 hours ago
Novartis AG (ADR) (NYSE:NVS) declared that the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee has mutually voted in favor of admiring AIN457 a selective interleukin-17A inhibitor for the treatment of moderate to severe plaque psoriasis in ...
Volatile Movements - Novartis AG (ADR) (NYSE:NVS), Garmin Ltd. (NASDAQ ...
Investor Wired (press release) - 23 hours ago
Novartis AG (ADR) (NYSE:NVS) offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical ...
Stocks Alert: Novartis AG (ADR) (NYSE:NVS), Chimerix Inc (NASDAQ:CMRX ...
Street Newswire - Oct 8, 2014
Novartis AG (ADR) (NYSE:NVS) said three members of its executive committee will leave the health-care company following the completion of the sales of its animal health, OTC drugs, and vaccine units to Eli Lilly (LLY) and GlaxoSmithKline (GSK).
Novartis's Signifor Closer To EU Approval
Bidness ETC - Sep 28, 2014
Novartis's Signifor is capable of treating acromegaly in adults, who are unable to go through a surgery as an alternative option, and those on whom first-generation somatostatin analogues (SSAs), including Novartis's Sandostatin LAR, have not worked ...
Novartis Releases Positive Phase 3 Results For Psoriatic Arthritis Drug
Bidness ETC - Sep 25, 2014
Novartis AG (ADR) (NVS) today released top line results for two late-stage pivotal studies, which evaluated its novel drug secukinumab as a treatment for psoriatic arthritis (PsA).
Pharma Stocks To Look Out For This Week
Bidness ETC - Oct 13, 2014
The US Food and Drug Administration (FDA) is also expected to release briefs for the Advisory Committee's meeting next week to give recommendations on Novartis AG (ADR)'s (NVS) secukinumab and Vertex Pharmaceuticals Incorporated's (VRTX) ...
Eye Catching Stocks: EXCO Resources Inc (NYSE:XCO), Novartis AG (ADR ...
StreetWise Report - Oct 13, 2014
Novartis AG (ADR) (NYSE:NVS) presents data at EADV showing reliable efficiency of AIN457 in clearing skin of psoriasis patients (NVS) : new investigation of AIN457 (secukinumab) Phase III studies explains that treatment with secukinumab 300 mg resulted ...
Sizzling news - Novartis AG (ADR) (NYSE:NVS), Royal Dutch Shell plc (NYSE ...
Techsonian (press release) - Sep 30, 2014
Manhattan, NY- September 30, 2014 - (Techsonian) - Novartis AG (ADR) (NYSE:NVS)offers patented prescription medicines in a variety of therapeutic areas, including oncology; most important care and established medicines; specialty care, such as ...